Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Core Insights - Corvus Pharmaceuticals has appointed Richard van den Broek to its board of directors, bringing over 30 years of experience in the life sciences industry [1][2] - The company is focused on advancing ITK inhibition as a novel approach to immunotherapy for various cancers and immune diseases [3] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing ITK inhibition, with its lead product candidate being soquelitinib, an investigational oral small molecule drug [3] - The company is also working on other clinical-stage candidates targeting a range of cancer indications [3] Leadership Experience - Richard van den Broek has a strong background in biotechnology, having previously served on the board of Pharmacyclics, where he contributed to the development of the first BTK inhibitor for lymphomas and immune diseases [2] - He is currently the managing partner at HSMR Advisors and has held directorships at Pulse Biosciences and Cogstate [2]